• KEYWORDS: diabetic retinopathy; matrix metalloproteinase-9; polysialylated neural cell adhesion molecule; retinal ganglion cells
INTRODUCTION

D
iabetic retinopathy (DR) is a common complication of diabetes. It can cause blindness in humans if left undiagnosed and untreated. Proliferative DR leads to intraretinal and intravitreal haemorrhages, glial cell proliferation and neovascularization, and tractional retinal detachment. Effects of diabetes on the retina have been studied in rodent models [1] [2] [3] . In animals, the most frequently used model is the streptozotocin (STZ) diabetic model [4] [5] . STZ is particularly toxic to the insulin-producing beta-cells of the pancreas in mammals and, depending on the dose, it can induce either Type 1 or Type 2 diabetes [6] . It is well established that DR damages retinal vasculature in rodents [7] [8] [9] . It has been shown that retinal ganglion cells (RGCs) are affected in both human and experimental diabetes. In diabetic rats and mice, RGCs undergo apoptosis and Müller cells are activated [3, [10] [11] .
However, some studies have failed to detect the degeneration of the RGCs in diabetic mice [12] . This discrepancy is probably due to the different sensitivity of mice and rats to STZ [13] . Neural cell adhesion molecule (NCAM) is a cell surface glycoprotein of the immunoglobulin superfamily of adhesion molecules. Polysialic acid (PSA) comprises alpha 2-8-linked sialic acid, and it is almost exclusively found attached to NCAM in mammals. In the central nervous system (CNS), it has been established that polysialylated neural cell adhesion molecule (PSA-NCAM) plays a role in synaptic plasticity, axon growth and migration, mediates cell interactions, and promotes the survival of neurons during development and cell regeneration. During embryogenesis, PSA is highly enriched on NCAM in many regions of the CNS but levels of polysialylated NCAM decrease soon after birth [14] [15] . However, it persists in the mature brain in the regions where ongoing plasticity and neurogenesis occur [16] . During development, NCAM is highly sialylated on the surface of cells in all retinal layers [17] . In adulthood, PSA-NCAM is expressed abundantly by astrocytes and endfeet of Müller cells in mice [17] [18] . Expression of NCAM by astrocytes was found in the human optic nerve head [19] . Human retinal pigment epithelial cells demonstrated expression of NCAM [20] . However, the roles of PSA-NCAM in the human retina are still unclear. Müller cells refer to radial cell glia, and they provide architectural support stretching radially across the thickness of the retina. In the adult retina, astrocyte cell bodies and processes are almost exclusively confined to the nerve fiber layer (NFL) and ganglion cell layer (GCL) of the retina [21] [22] . The soma of ganglion cells is covered by a close-fitting sheath formed by Müller cells. Intraretinal length of RGC axons is partly vested by both astrocytes and Müller cells [23] , and PSA-NCAM stays in close proximity to the RGC layer in adulthood. Glial fibrillary acidic protein (GFAP) is widely used as a marker to detect astrocytes and Müller cells. Removal of PSA from NCAM enhanced RGC degeneration in the normal retina and following optic nerve transection or administration of the neurotoxin kainic acid [24] . Mice with constitutive deficiency of NCAM demonstrated earlier RGC loss following optic nerve cut [25] . It was shown that PSA-NCAM can be cleaved extracellularly by matrix metalloproteinase-9 (MMP-9) [26] .
MMPs are zinс-containing endopeptidase. These enzymes are capable of degrading all kinds of extracellular matrix proteins. It was demonstrated in the several studies that MMP-9 is the most abundantly present in the retina during different pathological conditions including DR. Thus, the aim of this study was to explore whether or not DR is associated with alterations in PSA-NCAM expression/distribution in the adult mouse retina and if it influences RGC survival. [27] . Control mice were injected with vehicle only. Mice were screened for diabetes beginning at one week after the last injection of STZ by measuring glucose levels in a drop of blood obtained from the tail (glucometer GLUCOCARD™ X-METER). Insulin was not administered to the animals. Blood glucose levels and weight of the animals were measured once weekly. Mice were euthanized at two months after the onset of diabetes.
MATERIALS AND METHODS
Retinal Ganglion Cell Density Analyses RGC staining was performed in wholemount retinas using a Brn3a marker [28] [29] as it was done previously [24] . To evaluate the density of Brn3a-positive cells a stereology system comprising an Olympus BX-51 microscope and Visiopharm Integrator System (Version 3.6.5.0, Denmark) was applied. Forty visual fields (625 µm 2 ) were randomly sampled for each retina. The average density of Brn3a-positive cells in one retina was quantified per mm 2 for each animal in control (n=6) and diabetic (n=6) groups. Microglial Cell Density Analysis Microglial cell staining was done on the retinal sections using an Iba1 marker [30] . Mice were perfused and eye cups were sectioned at 18 μm making use of a cryostat (Leica Biosystems CM1850, Germany) as it was described before [24] . Endogenous peroxidase activity was blocked with 3% H 2 O 2 . Then retinal sections were incubated with primary goat anti-Iba1 antibody (Abcam, USA), diluted 1:100 in blocking solution containing 3% rabbit serum overnight, followed by incubation with biotinylated rabbit anti-goat IgG antibody (Vector Laboratories, USA), and diabetic (n=6) groups. Immunoblotting Analysis Tissue preparation, supernatants resolving and proteins transferring onto membranes was done as previously described [24] . Afterwards the membranes were incubated with Odyssey Blocking Buffer (LI-COR Biotechnology, USA). Primary antibodies: mouse anti-PSA-NCAM antibody (1:1000; IgM, clone: 2-2B; AbCys, France) or mouse anti-GFAP antibody (1:1000; IgG, clone 2-A-5, Chemicon, UK) or rabbit anti-β-actin antibody (1:5000; Sigma, St. Louis, USA) were applied overnight. Then the membranes were incubated with the secondary antibodies: biotinylated goat anti-mouse IgM antibody (1:2000; Vector Laboratories, Inc. USA), IR Dye 680 LT Streptavidin (1:10 000; LI-COR, Germany) or goat anti-mouse IR Dye 680 LT antibody (1:10 000; LI-COR, Germany) or goat anti-rabbit IR-Dye 800 CW antibody (1:10 000; LI-COR, USA). The membranes were analysed with Odyssey CLx Infrared Imaging System (USA).
The proteins' optical density ratios were then computed.
PSA-NCAM, GFAP, MMP-9 Immunohistochemistry
For PSA-NCAM, GFAP, and MMP-9 immunohistochemistry, three sections per animal for each protein were chosen randomly from control (n=6) and diabetic (n=6) groups. Endogenous peroxidase activity was blocked with 3% H 2 O 2 .
Next the sections were incubated with primary antibodies: mouse anti-PSA-NCAM antibody (1:400; IgM, clone: 2-2B; AbCys, France) or rabbit anti-GFAP antibody (1:1000; Dako, Denmark) or goat anti-MMP-9 antibody (1:500; Abcam, USA) followed by incubation with appropriate biotinylated anti-mouse, anti-rabbit or anti-goat antibodies (1:200; IgM, Vector Laboratories, Inc., USA). PSA-NCAM, GFAP and MMP-9 proteins were visualized using the peroxidase method (Vectastain ABC kit and Peroxidase substrate kit DAB, Vector Laboratories, USA). The sections were air-dried and mounting medium (Roti-Histokitt II, Germany) was laid on. Immunoreactivity for PSA-NCAM, GFAP and MMP-9 were observed using an Olympus BX-51 microscope. For immunofluorescent co-expression of PSA-NCAM and astrocyte marker (GFAP), sections were incubated with a mixture of mouse anti-PSA-NCAM antibody (1:400; IgM, clone: 2-2B; AbCys, France) and rabbit anti-GFAP antibody (1:500; Dako, Denmark). Secondary antibodies: Alexa Fluor 594 goat anti-mouse IgM (1:500; Invitrogen Molecular probes, USA) and Alexa Fluor 488 goat anti-rabbit IgG (H+L) (1:500; Invitrogen Molecular probes, USA) were used. Fluorescence signals were detected with a confocal microscope LSM 510 (Zeiss, Germany) and further analysed for the co-localization of PSA-NCAM signal with GFAP. DP55561-10, 561 nm and Argon/2 458, 477, 488, 514 nm lasers were used.
Analysis of PSA-NCAM and MMP-9 Immunoreactivity
Quantification of intensity of PSA-NCAM and MMP-9 immunoreactivity in the retina sections was evaluated in the following areas: NFL and GCL, inner plexiform layer (IPL) and inner nuclear layer (INL), outer plexiform layer (OPL) and outer nuclear layer (ONL). Mean gray value (MGV) of immunopositive profiles was measured using ImageJ software. Images were grey-scaled to 8-bit, and a grid overlay was applied. MGV in the crosses of the grid was measured in each area of interest for immunopositive profile and in the background. MGV of 8-bit images in ImageJ reflects an average intensity of pixels over a range of 0 (black) to 255 (white). MGV of each area was then expressed as a ratio, which was called the immunoreactivity index (IR index) [31] [32] . The IR index is: IR index=(1-I cell /I bg )×100, where I cell is the MGV of the immunopositive profile, I bg is the MGV of the background in that field. The IR index increases with immunostaining intensity.
Statistical Analysis
The results are expressed as the mean±SEM. Statistical analyses were performed using MannWhitney (non-parametric) or Student's t-test (parametric), where appropriate. Two-way ANOVA for repeated measures was used to assess the changes in the body weight.
RESULTS
Development of Streptozotocin Diabetes in Mice
The administration of STZ resulted in the rapid and stable rise in glucose levels. All animals demonstrated elevated blood glucose levels (P<0.05, Student's t-test) already at the end of the first week 28±1.8 mmol/L (n=12). At the end of the second week 80% of mice and at the third week all animals (n=12) demonstrated glucose levels 33 mmol/L (the highest detection level by the glucometer) and were considered to be diabetic (Figure 1) . In control animals, the glucose levels were 8.9± 1.2 mmol/L (n=12). At two months after the onset of diabetes, treated mice weighed significantly less than control mice (Figure 1 ). For the body weight changes, a two-way ANOVA demonstrated a significant effect of treatment (F 1,84 =162; P<0.0001), a significant effect of time (F 5,84 =23.93; P<0.0001) and a significant effect of interaction (F 5,84 =9.419; P<0.0001).
Changes in the Density of Retinal Ganglion Cells and Microglial Cells in Diabetic Mice
To examine whether diabetes affects the density of RGCs, we performed Brn3a immunohistochemistry in wholemount retinas of diabetic and control animals. Brn3a has been shown to be specifically expressed by RGCs in mice and can be used as an efficient marker to identify and quantify RGCs [28] [29] . Our experiments demonstrated significantly lower density of RGCs in diabetic mice at two months after onset of diabetes compared with Our experiments also demonstrated an increased density and hypertrophy of microglial (Iba1-positive) cells in diabetic retina (Table 1) , which suggests the existence of inflammation in DR.
PSA-NCAM in experimentally induced diabetic retinopathy
Redistribution of PSA-NCAM Immunohistochemical Signal in Diabetic Mice
Western blot did not reveal any changes in the total levels of PSA-NCAM protein in diabetic retina compared with controls ( Figure 2A ). Note: PSA-NCAM appears on the blot as a smear (180-220 kDa) due to the different size of PSA residues. Immunohistochemistry, however, detected a change in distribution of PSA-NCAM in the diabetic retina. In control sections, PSA-NCAM immunopositive cells were observed mainly in the NFL, GCL, with some also present in the IPL close to the RGCs (Figure 3 ). Much lower PSA-NCAM 
Changes in Glial Fibrillary Acidic Protein in the Retina of Diabetic Mice
The distribution of GFAP was also changed in the diabetic retina. GFAP-positive immunostaining was confined to astrocytes and Müller cells, primarily in the NFL, and GCL of both control and diabetic retinas (Figure 4 ). In addition, in diabetic retinas, GFAP immunoreactivity was also strongly enhanced in the IPL, INL, OPL, and ONL ( Figure 4) . In control retinas, GFAP immunopositive filaments were mostly located in the endfeet of Müller cells and in adjoining internal stem processes. In contrast, in diabetic mice, GFAPpositive immunostaining in Müller cells was evident in the body, as well as along both inner and outer stem processes and their branches. GFAP levels were increased by approximately 2.0-fold in the retina of diabetic mice compared with control retinas ( Figure 2B ). Co-localization studies of PSA-NCAM with GFAP demonstrated strong co-localization in control retina in the NFL and GCL. In contrast, in diabetic retina, PSA-NCAM was co-localized with GFAP primarily in the OPL and ONL ( Figure 5 ).
Changes in the Levels of Matrix Metalloproteinase-9 in the Retina of Diabetic Mice
It is well documented that DR is associated with the activation of metalloproteinases [33] [34] [35] .
Previous studies have demonstrated that a reduction in PSA-NCAM levels in neuronal cells might be due to the activation of MMP-9, which induces shedding of extracellular PSA-NCAM [26] . We therefore measured MMP-9 levels in the retinas of the diabetic mice. Immunohistochemical staining revealed a prominent enhancement of MMP-9 (approximately 1.9-fold) in the NFL and GCL of diabetic retina compared with controls ( Figure 6 ). In contrast, in IPL, INL, OPL, and ONL of diabetic retinas, MMP-9 levels were increased compared with controls albeit to a much lower extent ( Figure 6 ). DISCUSSION STZ is known as a compound with preferential toxicity toward pancreatic β-cells. It is commonly used for the induction of diabetes in mice [3, 27, 36] . In our experiments, two consecutive doses (90 mg/kg) of STZ administered over 24-hour intervals induced diabetes in mice on day 7 after the last administration [11, [37] [38] . Immunohistochemical analysis of PSA-NCAM expression demonstrated a dramatic change in PSA-NCAM distribution in the diabetic retina. In diabetic retinas, PSA-NCAM signal is remarkably decreased in the NFL, GCL and strongly enhanced in the OPL, and ONL, whereas in control retina, prominent PSA-NCAM immunoreactivity was found in the NFL and GCL. In control retinas, PSA-NCAM is expressed in the endfeet of the inner stem processes of Müller cells and in the astrocytes, which are in close contact with RGCs in NFL, and GCL. In contrast, in the diabetic retina, PSA-NCAM is located in the Müller cell bodies (INL) and in inner and outer stem processes and their side branches (primarily the OPL and ONL). The reduction of PSA-NCAM in GCL is associated with a decrease in RGC density in the diabetic retina. It was shown previously that PSA-NCAM supports RGC survival after optic nerve transection or after RGC injury [24, 18] . We therefore propose that the reduced PSA-NCAM level in NFL and GCL is at least in part responsible for the loss of RGCs in the diabetic retina. This proposal is supported by the data clearly demonstrating the supportive roles of PSA-NCAM for the survival on neuronal and retinal cells [18, 39] .
PSA-NCAM in experimentally induced diabetic retinopathy
The mechanisms by which PSA-NCAM promotes the survival of RGCs remain obscure. Some findings suggest that PSA-NCAM facilitates the brain derived neurotrophic factor (BDNF)-mediated phosphorylation of its receptor, TrkB, which promotes the neuronal survival [39] . BDNF and
TrkB are abundantly present in the retina and may have a neuroprotective effect on RGC [40] [41] [42] . Also, increased p75 signalling after PSA removal might enhance neurons death [43] . The reason why PSA-NCAM is reduced in the NFL and GCL is not clearly understood. Previous studies have demonstrated that MMPs might play a role in the regulation of PSA-NCAM levels [44] [45] . A recent study from our laboratory has demonstrated that MMP-9 can induce degradation of PSA-NCAM [26] . Our study demonstrated an approximate 1.9-fold increase in MMP-9 expression in the NFL and GCL in diabetic retinas compared with controls and this might explain the observed reduction of PSA-NCAM in these retinal layers. Previous studies also have demonstrated MMP-9 upregulation in the diabetic retina [46] [47] . It is proposed that MMP-9 is responsible for the degradation of PSA-NCAM in the NFL and GCL of diabetic retina. It was previously shown that intravitreal injection of MMP-9 inhibitor increases survival of RGC after retinal injury [48] . It should be noted, however, that a small but significant increase in MMP-9 levels was also observed in the other layers of the diabetic retina but it seems that this slight elevation cannot substantially impact PSA-NCAM shedding. The elevation of MMP-9 is most likely due to tissue inflammation, which accompanied DR. Furthermore, MMP-9 participates in angiogenesis by promoting endothelial cell migration, tubule formation, degradation of extracellular matrix and destruction of blood-retinal barrier [33] [34] [35] 49] .
Moreover, some evidence points to the fact that MMP-9 levels are higher in the vitreous humour in DR [34, 50] , which may additionally promote PSA-NCAM as well as NCAM cleavage in the inner part of the retina. It has been demonstrated also that PSA-NCAM is cleaved extracellularly by ADAM family metalloprotease [51] [52] . We do not exclude that ADAM metalloproteases are also involved in the shedding of PSA-NCAM in the inner part of diabetic retina. It is documented that diabetic hyperglycaemia causes hypoxia [53] and inflammation, which in turn induces proliferation of the processes of the Müller cells containing PSA-NCAM and GFAP. The role of an increase in PSA-NCAM in the IPL, INL and the OPL, and ONL of the diabetic retina is not clear but some evidence suggests that PSA-NCAM is involved in neovascularization in hypoxia-induced retinopathy [54] . PSA-NCAM may also act as a guide for proliferative and migratory Müller cell processes in DR [55] . In conclusion, our findings demonstrate that a decrease in PSA-NCAM levels in the NFL and GCL is associated with lower density of RGCs in diabetic retinas. A large increase in MMP-9 levels in NFL and GCL cause PSA-NCAM cleavage in the inner part of the retina. The causal relationship between PSA-NCAM and RGC survival, however, remains unclear. Currently the studies aiming at elucidation the roles of MMPs in the shedding of PSA-NCAM and the mechanisms by which PSA-NCAM regulates RGC survival are in progress in our laboratory.
